New labeling for the cholesterol-loweringagent simvastatin (Zocor, Merck) highlights the risks of myopathyand rhabdomyolysis with or without acute renal failure as side effectsof the drug alone or in combination.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

NEW WARNING: Simvastatin: Myopathy risk

Newsletter